Pertuzumab

Perjeta

Hoofdindicatie

Maagkanker

Extended indication

Lorem ipsum dolor site amet.    

Product

Manufacturer

Roche

Registration

Submission date

7-2021

Expected registration date

8-2020

Expected cost per patient per year

Cost

> € 4.000

Other information

Sources

Research report as published in consectetur sit amet on January 2020.